The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis
Abstract
Purpose: The epidermal growth factor receptor (EGFR) is frequently overexpressed in non–small-cell lung carcinoma (NSCLC), and EGFR inhibitors are promising new therapeutic agents. The molecular mechanisms responsible for EGFR overexpression are poorly understood. Materials and Methods: Gene copy number and protein status of EGFR were investigated in microarrayed tumors from 183 NSCLC patients, including squamous cell carcinoma (SCC; 89 patients) and non-SCC (94 patients) histologies. Protein expression was assessed by immunohistochemistry on a scale from 0 to 400 (percentage of positive cells × staining intensity). Gene and chromosome 7 copy numbers were identified by fluorescent in situ hybridization (FISH). Results: EGFR protein overexpression was observed in 62% of the NSCLC (25% scored 201 to 300; 37% scored 301 to 400), more frequently in SCC than non-SCC (82% v 44%; P < .001), and in 80% of the bronchioloalveolar carcinomas. The prevalent FISH patterns were balanced disomy (40%) and trisomy (38%) for EGFR gene and chromosome 7 (40%), whereas balanced polysomy was seen in 13% and gene amplification was seen in 9% of the patients. Gene copy number correlated with protein expression (r = 0.4; P < .001). EGFR overexpression or high gene copy numbers had no significant influence on prognosis. Conclusion: EGFR overexpression is frequent in NSCLC, is most prominent in SCC, and correlates with increased gene copy number per cell. High gene copy numbers per cell showed a trend toward poor prognosis. It will be important to evaluate EGFR gene and EGFR protein status and signal protein expression to properly interpret future clinical trials using EGFR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Jemal, A., Thomas, A., Murray, T., & Thun, M. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.1.23 · Cited by 2,917
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Global cancer statistics in the year 2000
Parkin, D. M. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00486-7 · Cited by 2,445
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Ciardiello, F., & Tortora, G. (2001) · PubMed · Cited by 977
Pauletti, G., Dandekar, S., Rong, H., Ramos, L., Peng, H., Seshadri, R., & Slamon, D. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.21.3651 · Cited by 670
Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.
Moscatello, D. K., Holgado-Madruga, M., Godwin, A. K., Ramirez, G., Gunn, G. R., Zoltick, P. W., Biegel, J. A., Hayes, R. L., & Wong, A. J. (1995) · PubMed · Cited by 637
Ekstrand, A. J., Sugawa, N., James, C. D., & Collins, V. P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4309 · Cited by 602
Wikstrand, C. J., Hale, L. P., Batra, S. K., Hill, M. L., Humphrey, P. A., Kurpad, S. N., McLendon, R. E., Moscatello, D. K., Pegram, C. N., & Reist, C. J. (1995) · PubMed · Cited by 518
Cited by
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Epidermal growth factor receptor (EGFR) signaling in cancer
Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., De Feo, G., Caponigro, F., & Salomon, D. S. (2006) · Gene · doi:10.1016/j.gene.2005.10.018 · Cited by 2,038
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M.-S., Sakurada, A., Cutz, J.-C., Zhu, C.-Q., Kamel-Reid, S., Squire, J., Lorimer, I., Zhang, T., Liu, N., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,830
Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S., Danenberg, K., Domenichini, I., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,551
Self-citationKim, E. S., Hirsh, V., Mok, T., Socinski, M. A., Gervais, R., Wu, Y.-L., Li, L.-Y., Watkins, C. L., Sellers, M. V., Lowe, E. S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61758-4 · Cited by 1,242
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
Chu, I. M., Hengst, L., & Slingerland, J. M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2347 · Cited by 990
Gatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., De Rosa, F., Milanowski, J., Karnicka-Mlodkowski, H., Pesek, M., Serwatowski, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1474 · Cited by 881
Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction
Hou, J., Aerts, J., den Hamer, B., van IJcken, W., den Bakker, M., Riegman, P., van der Leest, C., van der Spek, P., Foekens, J. A., Hoogsteden, H. C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010312 · Cited by 755
The epidermal growth factor receptor family: Biology driving targeted therapeutics
Wieduwilt, M. J., & Moasser, M. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7440-8 · Cited by 751
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Franklin, W. A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J. R., Ciuleanu, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3958 · Cited by 703
Self-citationTakano, T., Ohe, Y., Sakamoto, H., Tsuta, K., Matsuno, Y., Tateishi, U., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.0793 · Cited by 695
Epidermal Growth Factor Receptor Targeting in Cancer
MENDELSOHN, J., & BASELGA, J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693
Pao, W., & Miller, V. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.799 · Cited by 631
Integrative Proteomic Characterization of Human Lung Adenocarcinoma
Xu, J.-Y., Zhang, C., Wang, X., Zhai, L., Ma, Y., Mao, Y., Qian, K., Sun, C., Liu, Z., Jiang, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.043 · Cited by 612
Pirker, R., Pereira, J. R., von Pawel, J., Krzakowski, M., Ramlau, R., Park, K., de Marinis, F., Eberhardt, W. E., Paz-Ares, L., Störkel, S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70318-7 · Cited by 576
Hirsch, F. R., Varella-Garcia, M., McCoy, J., West, H., Xavier, A. C., Gumerlock, P., Bunn, P. A., Franklin, W. A., Crowley, J., & Gandara, D. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.2823 · Cited by 574
Self-citationKelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4824 · Cited by 573
Chung, C. H., Ely, K., McGavran, L., Varella-Garcia, M., Parker, J., Parker, N., Jarrett, C., Carter, J., Murphy, B. A., Netterville, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2587 · Cited by 572
Self-citationCappuzzo, F., Marchetti, A., Skokan, M., Rossi, E., Gajapathy, S., Felicioni, L., del Grammastro, M., Sciarrotta, M. G., Buttitta, F., Incarbone, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1635 · Cited by 557
Self-citationHerbst, R. S., Johnson, D. H., Mininberg, E., Carbone, D. P., Henderson, T., Kim, E. S., Blumenschein, G., Lee, J. J., Liu, D. D., Truong, M. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.477 · Cited by 530
Witta, S. E., Gemmill, R. M., Hirsch, F. R., Coldren, C. D., Hedman, K., Ravdel, L., Helfrich, B., Dziadziuszko, R., Chan, D. C., Sugita, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1988 · Cited by 515
Self-citationDouillard, J.-Y., Shepherd, F. A., Hirsh, V., Mok, T., Socinski, M. A., Gervais, R., Liao, M.-L., Bischoff, H., Reck, M., Sellers, M. V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3030 · Cited by 492
Thatcher, N., Hirsch, F. R., Luft, A. V., Szczesna, A., Ciuleanu, T. E., Dediu, M., Ramlau, R., Galiulin, R. K., Bálint, B., Losonczy, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00021-2 · Cited by 479
Self-citationPoliti, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes & Development · doi:10.1101/gad.1417406 · Cited by 478
Soria, J.-C., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., Göker, E., Georgoulias, V., Li, W., Isla, D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00006-6 · Cited by 433
Amann, J., Kalyankrishna, S., Massion, P. P., Ohm, J. E., Girard, L., Shigematsu, H., Peyton, M., Juroske, D., Huang, Y., Stuart Salmon, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.226.65.1 · Cited by 436
Malka, D., Cervera, P., Foulon, S., Trarbach, T., de la Fouchardière, C., Boucher, E., Fartoux, L., Faivre, S., Blanc, J.-F., Viret, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70212-8 · Cited by 408
Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention
Dannenberg, A. J., Lippman, S. M., Mann, J. R., Subbaramaiah, K., & DuBois, R. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.112 · Cited by 404
Temam, S., Kawaguchi, H., El-Naggar, A. K., Jelinek, J., Tang, H., Liu, D. D., Lang, W., Issa, J.-P., Lee, J. J., & Mao, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6605 · Cited by 404
Mandrekar, S. J., & Sargent, D. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3701 · Cited by 404
Liu, Z., Hou, P., Ji, M., Guan, H., Studeman, K., Jensen, K., Vasko, V., El-Naggar, A. K., & Xing, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0273 · Cited by 390
Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
Tracy, S., Mukohara, T., Hansen, M., Meyerson, M., Johnson, B. E., & Jänne, P. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1905 · Cited by 374
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations
Wardell, C. P., Fujita, M., Yamada, T., Simbolo, M., Fassan, M., Karlic, R., Polak, P., Kim, J., Hatanaka, Y., Maejima, K., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.009 · Cited by 373
Cappuzzo, F., Varella-Garcia, M., Shigematsu, H., Domenichini, I., Bartolini, S., Ceresoli, G. L., Rossi, E., Ludovini, V., Gregorc, V., Toschi, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.111 · Cited by 369
Self-citationBaselga, J., Cortés, J., Im, S.-A., Clark, E., Ross, G., Kiermaier, A., & Swain, S. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5384 · Cited by 364
EGFR signaling pathway as therapeutic target in human cancers
Levantini, E., Maroni, G., Del Re, M., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 356
Chou, T.-Y., Chiu, C.-H., Li, L.-H., Hsiao, C.-Y., Tzen, C.-Y., Chang, K.-T., Chen, Y.-M., Perng, R.-P., Tsai, S.-F., & Tsai, C.-M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1981 · Cited by 317
Stabile, L. P., Lyker, J. S., Gubish, C. T., Zhang, W., Grandis, J. R., & Siegfried, J. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1872 · Cited by 309
Mechanisms for oncogenic activation of the epidermal growth factor receptor
Zandi, R., Larsen, A. B., Andersen, P., Stockhausen, M.-T., & Poulsen, H. S. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.06.023 · Cited by 303
Eberhard, D. A., Giaccone, G., & Johnson, B. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9858 · Cited by 300
EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus
Hanawa, M., Suzuki, S., Dobashi, Y., Yamane, T., Kono, K., Enomoto, N., & Ooi, A. (2006) · International Journal of Cancer · doi:10.1002/ijc.21454 · Cited by 298
Novel Prognostic Value of Nuclear Epidermal Growth Factor Receptor in Breast Cancer
Lo, H.-W., Xia, W., Wei, Y., Ali-Seyed, M., Huang, S.-F., & Hung, M.-C. (2005) · Cancer Research · doi:10.1158/0008-5472.338.65.1 · Cited by 290
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers
Ogiwara, H., Takahashi, K., Sasaki, M., Kuroda, T., Yoshida, H., Watanabe, R., Maruyama, A., Makinoshima, H., Chiwaki, F., Sasaki, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.009 · Cited by 289
Taube, J. M., Akturk, G., Angelo, M., Engle, E. L., Gnjatic, S., Greenbaum, S., Greenwald, N. F., Hedvat, C. V., Hollmann, T. J., Juco, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000155 · Cited by 283
Kim, M. A., Lee, H. S., Lee, H. E., Jeon, Y. K., Yang, H. K., & Kim, W. H. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03021.x · Cited by 283
Freed-Pastor, W. A., Lambert, L. J., Ely, Z. A., Pattada, N. B., Bhutkar, A., Eng, G., Mercer, K. L., Garcia, A. P., Lin, L., Rideout, W. M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.007 · Cited by 273
Hirsch, F. R., Herbst, R. S., Olsen, C., Chansky, K., Crowley, J., Kelly, K., Franklin, W. A., Bunn, P. A., Varella-Garcia, M., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0111 · Cited by 271
Self-citationThe Biology of Epidermal Growth Factor Receptor in Lung Cancer
Scagliotti, G. V., Selvaggi, G., Novello, S., & Hirsch, F. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040007 · Cited by 270
Self-citationHirsch, F. R., Varella-Garcia, M., Cappuzzo, F., McCoy, J., Bemis, L., Xavier, A. C., Dziadziuszko, R., Gumerlock, P., Chansky, K., West, H., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm003 · Cited by 268
Self-citationThe complexity of targeting EGFR signalling in cancer: From expression to turnover
Sebastian, S., Settleman, J., Reshkin, S. J., Azzariti, A., Bellizzi, A., & Paradiso, A. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.06.001 · Cited by 260
Rosell, R., Robinet, G., Szczesna, A., Ramlau, R., Constenla, M., Mennecier, B. C., Pfeifer, W., O’Byrne, K. J., Welte, T., Kolb, R., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm474 · Cited by 258
Han, W., Pan, H., Chen, Y., Sun, J., Wang, Y., Li, J., Ge, W., Feng, L., Lin, X., Wang, X., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018691 · Cited by 256
Combinatorial patterns of somatic gene mutations in cancer
Yeang, C.-H., McCormick, F., & Levine, A. (2008) · The FASEB Journal · doi:10.1096/fj.08-108985 · Cited by 251
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
Puca, L., Gavyert, K., Sailer, V., Conteduca, V., Dardenne, E., Sigouros, M., Isse, K., Kearney, M., Vosoughi, A., Fernandez, L., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav0891 · Cited by 214
Paz-Ares, L., Mezger, J., Ciuleanu, T. E., Fischer, J. R., von Pawel, J., Provencio, M., Kazarnowicz, A., Losonczy, G., de Castro, G., Szczesna, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70046-x · Cited by 133
Self-citationTNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer
Gong, K., Guo, G., Gerber, D. E., Gao, B., Peyton, M., Huang, C., Minna, J. D., Hatanpaa, K. J., Kernstine, K., Cai, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96148 · Cited by 98
Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer
Su, Y., Liu, Y., Behrens, C. R., Bidlingmaier, S., Lee, N.-K., Aggarwal, R., Sherbenou, D. W., Burlingame, A. L., Hann, B. C., Simko, J. P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121497 · Cited by 82
Casey, F. P., Baird, D., Feng, Q., Gutenkunst, R. N., Waterfall, J. J., Myers, C. R., Brown, K. S., Cerione, R. A., & Sethna, J. P. (2007) · IET Systems Biology · doi:10.1049/iet-syb:20060065 · Cited by 77
Wang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01911-5 · Cited by 66
Biomarkers in Lung Cancer: From Early Detection to Novel Therapeutics and Decision Making
Scott, A., & Salgia, R. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.6.577 · Cited by 59
Goss, G. D., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., Göker, E., Georgoulias, V., Li, W., Guclu, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0775 · Cited by 55
Histone Lysine Methylation Dynamics Control EGFR DNA Copy-Number Amplification
Clarke, T. L., Tang, R., Chakraborty, D., Van Rechem, C., Ji, F., Mishra, S., Ma, A., Kaniskan, H. Ü., Jin, J., Lawrence, M. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0463 · Cited by 50
Cavazzoni, A., Alfieri, R. R., Cretella, D., Saccani, F., Ampollini, L., Galetti, M., Quaini, F., Graiani, G., Madeddu, D., Mozzoni, P., et al. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-91 · Cited by 44
“non-small cell lung cancer (NSCLC) patients and their overexpression has been frequently correlated with a poor prognosis [3,4].”
BackgroundHingorani, P., Roth, M. E., Wang, Y., Zhang, W., Gill, J. B., Harrison, D. J., Teicher, B., Erickson, S., Gatto, G., Smith, M. A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0406 · Cited by 41
“Stainingwas assessed by determining the intensity (0–3) as well as percentage of positive cells and calculating an H score as described previously (14).”
MethodHingorani, P., Zhang, W., Zhang, Z., Xu, Z., Wang, W.-L., Roth, M. E., Wang, Y., Gill, J. B., Harrison, D. J., Teicher, B. A., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0758 · Cited by 28
Javed, S., Sood, S., Rai, B., Bhattacharyya, S., Bagga, R., & Srinivasan, R. (2021) · Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_709_20 · Cited by 13
Neal, A. S., Nunez, M., Lai, T., Tosevska, A., Morselli, M., Amneus, M., Zakhour, M., Moatamed, N. A., Pellegrini, M., & Memarzadeh, S. (2020) · Reproductive Sciences · doi:10.1007/s43032-020-00175-w · Cited by 11
Metadata
- Authors
- Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Di Maria, M. V., Veve, R., Bremnes, R. M., Barón, A. E., Zeng, C., & Franklin, W. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-10-15
- Volume
- 21
- Issue
- 20
- Pages
- 3798-3807
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2138604360
- Cited by
- 1,477
- References
- 31
- FWCI
- 48.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.